Combivir ViiV Healthcare BV · Authorised · authorised 18 Mar 1998 · ATC J05AR01
Therapeutic indication (EMA)
Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection.
Active substances
Lamivudine + Zidovudine
- SFDA 1
- US FDA 14
- EMA 2
- Health Canada 3
- US price lines 1
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| COMBIVIR F.C TAB | 300,150 mg,mg | Film-coated tablet · Oral use | 60 Blister | SAR 1091.55 | NCE · Prescription | Glaxo Saudi Arabia Ltd. | Valid |
Indications — CHI Daman Drug Formulary
HUMAN IMMUNODEFICIENCY VIRUS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LAMIVUDINE AND ZIDOVUDINE | 150MG;300MG | tablet · oral | HETERO LABS LTD V | Prescription | 3 Feb 2014 |
| LAMIVUDINE AND ZIDOVUDINE | 150MG;300MG | tablet · oral | HETERO LABS LTD III | Prescription | 17 Sep 2015 |
| LAMIVUDINE AND ZIDOVUDINE | 150MG;300MG | tablet · oral | AUROBINDO PHARMA | Prescription | 5 May 2017 |
| LAMIVUDINE AND ZIDOVUDINE | 150MG;300MG | tablet · oral | EPIC PHARMA LLC | Prescription | 10 Apr 2018 |
| LAMIVUDINE AND ZIDOVUDINE | 150MG;300MG | tablet · oral | MACLEODS PHARMS | Prescription | 29 Aug 2018 |
| LAMIVUDINE AND ZIDOVUDINE | 150MG;300MG | tablet · oral | CIPLA | Prescription | 7 Sep 2018 |
| COMBIVIR | 150MG;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | VIIV HLTHCARE | Discontinued | 26 Sep 1997 |
| LAMIVUDINE AND ZIDOVUDINE | 150MG;300MG | tablet · oral | CHARTWELL RX | Discontinued | 25 May 2011 |
| LAMIVUDINE AND ZIDOVUDINE | 150MG;300MG | tablet · oral | LUPIN LTD | Discontinued | 15 May 2012 |
| LAMIVUDINE AND ZIDOVUDINE | 150MG;300MG | tablet · oral | AUROBINDO PHARMA LTD | Discontinued | 15 May 2012 |
| LAMIVUDINE AND ZIDOVUDINE | 150MG;300MG | tablet · oral | NATCO | Discontinued | 28 Aug 2014 |
| LAMIVUDINE AND ZIDOVUDINE | 150MG;300MG | tablet · oral | PHARMOBEDIENT | Discontinued | 13 May 2015 |
| LAMIVUDINE AND ZIDOVUDINE | 150MG;300MG | tablet · oral | PHARMACARE | Discontinued | 17 Mar 2017 |
| LAMIVUDINE AND ZIDOVUDINE | 150MG;300MG | tablet · oral | PHARMOBEDIENT | Discontinued | 12 Aug 2019 |
EMA European Union — centrally authorised medicines
Lamivudine/Zidovudine Teva Teva Pharma B.V. · Withdrawn · authorised 28 Feb 2011 · ATC J05AR01
Therapeutic indication (EMA)
Lamivudine/Zidovudine Teva is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV) infection.
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-LAMIVUDINE-ZIDOVUDINE | 02375540 | 150 MG; 300 MG | TABLET · ORAL | APOTEX INC |
| AURO-LAMIVUDINE/ZIDOVUDINE | 02414414 | 300 MG; 150 MG | TABLET · ORAL | AURO PHARMA INC |
| JAMP LAMIVUDINE / ZIDOVUDINE | 02502801 | 300 MG; 150 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | LAMIVUDINE-ZIDOVUDINE TABLET | $0.77072 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.4.2.5. Fixed-dose combinations of antiretrovirals · core
Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
Oral > Solid: 30 mg + 60 mg Tablet (EMLc); 150 mg + 300 mg Tablet (EML)
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.